BACKGROUND: Antithrombotics and profibrinolytics are indicated in several clinical thrombophilic conditions such as @entity5226 . @entity17007 , a glycosaminoglycan, shows an antithrombotic activity with low anticoagulant effect. The aim of the study was to evaluate the efficacy and the safety of heparansulphate (100 mg b.i.d.) versus mesoglycan (50 mg b.i.d.), both administered for three months in @entity1 with @entity5226 . METHODS: The trial was performed in an open-label, controlled, with parallel and randomized groups, design. Thirty @entity1 , with @entity4096 and a history of @entity49 were enrolled. Coagulative and fibrinolytic parameters (PT, aPTT, euglobulin lysis time, @entity2002 , D-dimer, @entity3479 , @entity2289 ) and signs and symptoms (cramps, @entity809 , itch, @entity4 , @entity158 , skin trophism) were assessed at enrollment, 15 days later after the pharmacological washout period and after 1, 2, 3 months of treatment. Safety was evaluated by monitoring any adverse event during the study and performing clinical laboratory tests at the beginning and at the end of treatment. RESULTS: The two drugs showed a superimposable efficacy and very good tolerability. Coagulative and fibrinolytic parameters were positively affected by both treatments and the clinical benefit was particularly evident in the heparansulphate group with a significant decrease "between times" of @entity158 , @entity4 , @entity809 and itching. CONCLUSIONS: These data support the use of heparansulphate, and in general of glycosaminoglycans, in the @entity751 .

[Heparan sulfate in the therapy of XXXX . Evaluation of the efficacy and tolerability as compared to mesoglycan].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2002 :: ('2244', 'Gene') :: ['fibrinogen'] @entity17007 :: ('CHEBI:28815', 'Chemical') :: ['Heparansulphate'] @entity2289 :: ('5054', 'Gene') :: ['PAI-1'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity809 :: ('MESH:D010292', 'Disease') :: ['paresthesia'] @entity49 :: ('MESH:D019851', 'Disease') :: ['venous thrombosis'] @entity5226 :: ('MESH:D011186', 'Disease') :: ['postphlebitic syndrome'] @entity751 :: ('MESH:D013577', 'Disease') :: ['postflebitic syndrome'] @entity4096 :: ('MESH:D014689', 'Disease') :: ['chronic venous insufficiency'] @entity158 :: ('MESH:D010146', 'Disease') :: ['local pain'] @entity3479 :: ('5327', 'Gene') :: ['t-PA']
@entity5226 :: (MESH:D011186,Disease) :: ['postphlebitic syndrome']
